inodiftagene vixteplasmid
Gene therapyexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2008 (NCT00595088)
Timeline
Indications
Mechanism of action
- Tumor cell linesSupplementation
Tumor cell lines supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594478 ↗
Also known as
- bc-819
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03719300 | Phase 2 | Dec 11, 2018 | Anchiano Therapeutics |
| NCT01413087 | Phase 2 | Sep 1, 2011 | Anchiano Therapeutics |
| NCT00826150 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2009 | Anchiano Therapeutics, Hebrew University, Tel Aviv University, University of Haifa |
| NCT00595088 | Phase 2 | Jan 1, 2008 | Anchiano Therapeutics, University of Arizona |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Anchiano Therapeutics | For profit | 4 | 4 | 1 | 2008 |
| Hebrew University | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Tel Aviv University | Academic/Hospital | 1 | 0 | 1 | 2009 |
| University of Arizona | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of Haifa | Academic/Hospital | 1 | 0 | 1 | 2009 |
5 organizations
Page 1 / 1